share_log

Philips Respironics Reached Final Agreement On The Consent Decree With The DOJ And FDA, Creating A Clear Path Forward

Benzinga ·  Apr 10 03:26

Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips' subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA. As previously stated:

  • The consent decree primarily focuses on Philips Respironics' business operations in the US.
  • It provides clarity and a roadmap to demonstrate compliance with regulatory requirements and to restore the Philips Respironics business.
  • Philips Respironics is committed to meeting the consent decree requirements, while continuing to service healthcare providers and their patients under agreed conditions in the US and outside the US.
  • The 2023 – 2025 Group financial outlook takes the consent decree into account and remains unchanged.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment